IPA‑AhR Signaling Modulates Vascular Health via a CYP1A1‑Dependent Biphasic Mechanism Predicted by Baseline fldC Abundance

Hypothesis

Indole‑3‑propionic acid (IPA) exerts opposite effects on arterial stiffness depending on the intestinal microbial capacity to produce IPA (fldC gene abundance) and host intestinal CYP1A1 expression. In individuals with high fldC abundance and low baseline CYP1A1, IPA supplementation activates AhR‑Nrf2 cross‑talk in intestinal epithelial cells, increasing release of IPA‑loaded extracellular vesicles that reach the vasculature and promote endothelial nitric oxide synthase (eNOS) activity, thereby reducing pulse wave velocity (PWV). Conversely, in those with high fldC but elevated CYP1A1, IPA triggers AhR‑driven CYP1A1 induction, generating reactive oxygen species that uncouple eNOS and increase PWV. This predicts a U‑shaped dose‑response curve for arterial stiffness that shifts left or right according to the fldC/CYP1A1 ratio.

Mechanistic Rationale

1. AhR‑Nrf2 Crosstalk in Gut Epithelium – AhR activation by IPA can induce Nrf2‑dependent antioxidant genes (e.g., HO‑1, NQO1) in enterocytes, enhancing vesicle biogenesis (exosomes) that encapsulate IPA and transport it systemically. This pathway is suppressed when CYP1A1 is highly expressed because AhR preferentially drives the xenobiotic metabolism program over Nrf2 activation.
2. Extracellular Vesicle Mediated Delivery – Gut‑derived vesicles fuse with endothelial cells, releasing IPA that engages endothelial AhR at low concentrations, stimulating eNOS via PI3K/Akt phosphorylation and reducing oxidative stress.
3. CYP1A1‑Dependent Oxidative Switch – High CYP1A1 metabolizes IPA to reactive intermediates, increasing superoxide production that oxidizes tetrahydrobiopterin (BH4), uncoupling eNOS and elevating vascular ROS, which promotes arterial stiffening.
4. Microbiome‑Host Interaction – fldC abundance directly determines luminal IPA production; host CYP1A1 polymorphisms or inducible expression (e.g., via diet or pollutants) set the threshold at which IPA shifts from antioxidant to pro‑oxidant signaling.

Testable Predictions

• Prediction 1: In a double‑blind, crossover trial, participants stratified into high fldC/low CYP1A1 vs. high fldC/high CYP1A1 groups will show opposite changes in brachial‑ankle PWV after 8 weeks of oral IPA (20 mg/kg/day). The first group will exhibit a ≥5 % PWV reduction; the second group will show a ≥5 % PWV increase.
• Prediction 2: Plasma vesicle‑associated IPA will rise proportionally to fecal fldC abundance only in the low CYP1A1 stratum, correlating with improvements in flow‑mediated dilation (FMD).
• Prediction 3: Peripheral blood mononuclear cell CYP1A1 mRNA will increase after IPA supplementation exclusively in the high CYP1A1 stratum, and this increase will mediate the PWV rise (mediation analysis).

Experimental Design

1. Cohort: 120 adults aged 50‑75, screened for serum IPA < 150 ng/mL and stratified by stool fldC qPCR (high > median, low ≤ median) and PBMC CYP1A1 baseline expression (high/low).
2. Intervention: IPA or matched placebo for 8 weeks, 4‑week washout, crossover.
3. Outcomes: Primary – change in brachial‑ankle PWV; secondary – plasma vesicle IPA (NTA‑Western), FMD, serum IL‑6/TNFα, urinary 8‑iso‑PGF2α, and gut microbiome shotgun metagenomics for fldC.
4. Analysis: Mixed‑effects models with interaction terms (treatment × fldC stratum × CYP1A1 stratum); mediation analysis to test CYP1A1 induction as intermediary.

Falsifiability

If IPA supplementation does not produce divergent PWV changes based on the fldC/CYP1A1 stratification, or if vesicle‑associated IPA fails to correlate with fldC abundance irrespective of CYP1A1, the hypothesis is refuted. Similarly, absence of CYP1A1 upregulation in the high stratum would invalidate the oxidative switch mechanism.

Significance

Establishing a microbiome‑host biomarker (fldC/CYP1A1 ratio) that predicts IPA’s vascular impact would enable precision nutrition, resolve the AhR paradox, and translate IPA from mechanistic curiosity to a clinically actionable longevity intervention.